Rein Therapeutics, Inc.
RNTXNasdaqCIK 1420565HealthcareFiscal year ends Dec 31
Reports and events: 164 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-0416:31 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-383726 |
| 2026-08-2716:05 ET | 8-K | 3.01 Delisting notice | 0001193125-26-371260 |
| 2026-08-1406:34 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-350270 |
| 2026-07-2116:10 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-310315 |
| 2026-06-0809:17 ET | DEF 14A | Proxy statementPeriod 2026-07-20 | 0001193125-26-260809 |
| 2026-05-1507:56 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-225352 |
| 2026-05-0416:12 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-204006 |
| 2026-04-2817:29 ET | S-1 | Registration statement | 0001193125-26-187803 |
| 2026-04-2706:51 ET | 10-K/A | Annual report, amendedPeriod 2025-12-31 | 0001193125-26-178787 |
| 2026-03-2616:36 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-126385 |
| 2026-03-0206:02 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-084012 |
| 2026-02-1916:37 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-059545 |
| 2026-01-1617:25 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-015524 |
| 2025-12-1117:20 ET | 8-K | 1.02 Termination of a material agreement | 0001193125-25-316225 |
| 2025-11-1408:00 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-281622 |
| 2025-11-0307:45 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-261706 |
| 2025-10-2417:08 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-25-250175 |
| 2025-10-0907:45 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-235152 |
| 2025-09-2208:00 ET | 8-K | 8.01 Other events | 0001193125-25-210050 |
| 2025-09-0908:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-25-198816 |
| 2025-09-0317:03 ET | S-1 | Registration statement | 0001193125-25-195041 |
| 2025-08-1908:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-183073 |
| 2025-08-1416:03 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-108836 |
| 2025-07-3009:04 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-25-168830 |
| 2025-07-2316:01 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-163400 |
| 2025-07-1116:01 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-158192 |
| 2025-06-2416:01 ET | 8-K | 8.01 Other events | 0001193125-25-145711 |
| 2025-06-1216:24 ET | 8-K | 8.01 Other events | 0001193125-25-139950 |
| 2025-05-1516:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-120824 |
| 2025-05-1516:06 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-072607 |
| 2025-05-1216:30 ET | DEF 14A | Proxy statementPeriod 2025-06-24 | 0001193125-25-117820 |
| 2025-04-3017:27 ET | 10-K/A | Annual report, amendedPeriod 2024-12-31 | 0001193125-25-107666 |
| 2025-04-2208:58 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-25-087955 |
| 2025-04-1716:14 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001193125-25-084340 |
| 2025-04-0716:02 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-051566 |
| 2025-01-1016:06 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-004443 |
| 2024-11-1416:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-258568 |
| 2024-11-1416:03 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-127019 |
| 2024-08-2116:17 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-204425 |
| 2024-08-1417:23 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-200739 |
| 2024-08-1417:12 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-097199 |
| 2024-07-2616:36 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-186279 |
| 2024-07-0908:30 ET | DEF 14A | Proxy statementPeriod 2024-08-20 | 0001193125-24-176585 |
| 2024-06-0506:58 ET | 8-K | 5.08 Item not in the standard list; 8.01 Other events | 0001193125-24-154675 |
| 2024-05-1617:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-140688 |
| 2024-05-1517:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-139510 |
| 2024-05-1517:08 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-060583 |
| 2024-05-0117:25 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-127657 |
| 2024-05-0108:40 ET | 8-K | 2.02 Results of operations; 8.01 Other events | 0001193125-24-126425 |
| 2024-04-2908:33 ET | 10-K/A | Annual report, amendedPeriod 2023-12-31 | 0001193125-24-120235 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.